Abstract A major advancement in therapy of type 1 diabetes mellitus (T1DM) is the discovery of new treatment which avoids and even replaces the absolute requirement for injected insulin. The need for multiple drug therapy of comorbidities associated with T1DM increases demand for developing novel therapeutic alternatives with new mechanisms of actions. Compared to other sulphonylurea drugs used in the treatment of type 2 diabetes mellitus, gliclazide exhibits a pleiotropic action outside pancreatic b cells, the so-called extrapancreatic effects, such as antiinflammatory and cellular protective effects, which might be beneficial in the treatment of T1DM. Results from in vivo experiments confirmed the positive effects of gliclazide in T1DM that are even more pronounced when combined with other hypoglycaemic agents such as probiotics and bile acids. Even though the exact mechanism of interaction at the molecular level is still unknown, there is a clear synergistic effect between gliclazide, bile acids and probiotics illustrated by the reduction of blood glucose levels and improvement of diabetic complications. Therefore, the manipulation of bile acid pool and intestinal microbiota composition in combination with old drug gliclazide could be a novel therapeutic approach for patients with T1DM.
Introduction
The increasing global burden of diabetes mellitus (DM) makes this a disease of considerable concern at the patient level as well as at the public health level considering the reduced life expectancy of patients and high costs of treatment [1] . Despite strict glycaemic control and the fact that new and more effective drugs are continuously appearing on the market, diabetic patients still suffer from the disease symptoms and its complications [2] . The need for multiple drug therapy of comorbidities associated with diabetes, increases demand for developing novel therapeutic alternatives with new mechanisms of action including targeting of multiple signalling pathways associated with etiopathogenesis of diabetes.
Besides well-known role of gliclazide in type 2 DM (T2DM), potential role of this drug in T1DM is gaining a greater importance since it was found that it might have beneficial effect, particularly in combination with other hypoglycaemic agents such as bile acids and probiotics that will be discussed in detail in further text. Namely, recent studies have shown a strong relationship between diabetes, disturbance in gut microflora composition and unbalanced secretion of bile acids [3] [4] [5] [6] [7] [8] . Therefore, manipulation of bile acid pool and commensal microbial composition in combination with old drug gliclazide could be a novel therapeutic approach for patients with T1DM.
Diabetes Mellitus (Type 1 and Type 2)
Diabetes is a disorder of chronic hyperglycaemia and has traditionally been subdivided into T1DM (with autoimmune destruction of insulin-secreting b cells) and T2DM (with insulin resistance and features of metabolic syndrome). However, this classification is oversimplified and diabetes is much more complex than being divided into these two types [9] .
Type 1 Diabetes Mellitus
T1DM (previously known as insulin-dependent) is a metabolic disorder that results from the progressive destruction of insulin-secreting b cells in the islets of Langerhans of the pancreas, leading to insulin insufficiency and the inability of the body to control glucose homeostasis [2] . Insulin therefore has to be replaced by regular subcutaneous injections, and blood glucose levels must be frequently monitored to manage the risk of hypoglycaemia. The main goal of the insulin replacement in patents with T1DM is to physiologically simulate normal insulin secretion maintaining basal levels and achieving peak levels at mealtimes. That requires huge effort and understanding of the underlying physiology [10] [11] [12] . However, there are two major disadvantages of external insulin replacement. Firstly, no feedback or suppression of insulin release is possible when levels of glucose fall increasing the risk of hypoglycaemia and the second difference is that insulin is administered peripherally, whereas b cells secrete insulin in the portal system primarily targeting the liver [12] .
Globally, T1DM continues to increase in prevalence at an alarming rate. Onset of the disease occurs typically in children and adolescents, but the disease can develop at any age.
In general, the incidence increases with age and the incidence peak is at puberty. In childhood, the incidence of T1DM is similar between males and females; however, wide variations exist between different populations and different geographical areas. The highest incidence rate is observed in northern European countries, particularly in Finland, and in the Mediterranean island of Sardinia, while China and Venezuela has the lowest risk [13] [14] [15] .
Although the pathogenesis of T1DM remains incompletely clear, the most accepted explanation is that disease is a chronic inflammatory disease which is triggered in genetically susceptible individuals by the dysfunction of the gut-mediated oral tolerance to ingested proteins and the consequent change in the bile acids metabolism [4] . The most common T1DM subtype (type 1a) has an autoimmune pathogenesis, and both auto-antibodies (IAA, ICA, IA-2, GAD65, ZnT8) and a genetic predisposition are frequently present [14] . Growing body of evidence has shown that environmental factors, with gut microbiota as the most important, can also modify diabetes development [16] . However, approximately 10% of patients diagnosed with T1DM are negative for autoimmune markers and 5% are persistently antibody-negative in follow-up evaluations [17] . Genetic mutations that affect b-cell function are possible aetiological factor in non-autoimmune T1D which has been postulated in SEARCH study [18] . Indeed, at least one form of insulin-deficient diabetes, neonatal diabetes mellitus (NDM), develops as a consequence of defects in the glucose-dependent signalling pathways in insulin secretion [19] [20] [21] . In these patients, b-cell mass is not initially reduced and hence insulin therapy is not necessarily appropriate. Indeed, most NDM patients who have mutations in one of the two subunits of the adenosine triphosphate (ATP)-sensitive potassium channel (SUR1 or Kir6.2) will robustly and repeatedly respond to sulfonylureas, circumventing the insulin secretory defect [22] . Accordingly, restoring insulin secretory response in T1D patients who still have silent although functional b-cells not only improves glycemic control but also often reduces the incidence of undesirable hypoglycaemic events.
People with diabetes are at significant risk with longterm damage, dysfunction, and failure of various organs, especially the heart, eyes, kidneys, nerves, and blood vessels that are proven to be dependent on the degree of glycaemic control in diabetic patients [2] . Patients with diabetes have an increased incidence of atherosclerotic cardiovascular, peripheral arterial and cerebrovascular disease. Hypertension and disturbance of lipoprotein metabolism are often found in people with diabetes [15, 23] . Major disturbances also include slower gut movement and microfloral overgrowth (especially of fermentation bacteria and yeasts due to the slightly more acidic gut contents) followed by rise in the concentration of secondary bile acids such as lithocholic acid [4] . Thus, the use of bile acids and probiotics in patients with diabetes may ameliorate complications and improve glycaemia as well. The main advance in T1DM therapy would be the discovery of treatments that avoid and even replace the absolute requirement for injected insulin [4] .
Type 2 Diabetes Mellitus
T2DM, formerly known as non-insulin-dependent diabetes mellitus, is a metabolic disorder characterized by insulin insensitivity as a result of insulin resistance, declining insulin production and eventual pancreatic b cell failure leading to a decrease in glucose transport into the liver, muscle cells and fat cells. The role of compromised a cell function has recently been recognized in the pathophysiology of T2DM. The onset of T2DM is most common for middle age and later life [23, 24] . T2DM results from interaction between genetic, environmental and behavioural risk factors [25] , and it is often associated with obesity, hypertension and insulin resistance which can result in the complete destruction of b cells of the pancreas leading to T1DM. Thus, T2DM may be controlled by diet and exercise and, unlike T1DM, does not always require the use of insulin. However, the term ''non-insulin dependent'' is an inaccurate term since many patients require insulin therapy at some time in the course of their disease [4] . Besides lifestyle modifications, many patients require drug therapy as well. Sulfonylureas have been recommended as first-line therapy in patients with preserved islet b-cell function in whom dietary and lifestyle modifications have proved to be insufficient [26] .
Potential Role of Gliclazide in T1DM
Gliclazide is a commonly prescribed drug for T2DM [27, 28] . Potential role of this drug in T1DM is gaining a greater importance since it was found that it might have beneficial effect particularly in combination with bile acids and probiotics that will be discussed in detail in further text.
Gliclazide belongs to the group of sulphonylureas that stimulate both basal insulin secretion and meal-stimulated insulin release via binding to b cell sulphonylurea receptor (SUR1, encoded by the ABCC8 gene), and possibly through a direct effect on intracellular calcium transport [28, 29] . SUR is found on the surface of pancreatic b cells closely linked to an ATP-sensitive potassium channel, and binding of gliclazide and other sulphonylureas blocks the efflux of potassium from the cell. Subsequent depolarization of the cell and change in the membrane potential activates the opening of membrane voltage-dependent calcium channels, allowing extracellular calcium to enter the cell. This increase in free intracellular calcium ion initiates chain of events leading to the release of insulin from b cells [30, 31] .
Sulfonylurea-dependent insulin secretion has been successfully demonstrated in NDM patients, as well as in carriers of hepatocyte nuclear factor 1a mutations, inflicting further investigation of the potential application of these drugs in T1D patients with defects in the pathway of glucose-stimulated insulin secretion [32, 33] . Favourable insulin secretagogue effects of sulfonylurea in T1D patients, particularly in those who are autoantibody negative, indicate that the fault in insulin secretion by the residual viable but quiescent b-cells may be surpassed without the need for lifelong insulin administration.
Specific emphasis on gliclazide application may be based on favourable emerging evidence. Individual sulfonylureas express a different affinity and selectivity for inhibition of the ATP-sensitive potassium channels present in pancreatic b-cell (containing SUR1 receptors) and cardiomyocytes (containing SUR2 receptors). Whereas gliclazide specifically inhibits channels containing SUR1 located in pancreatic b-cells, glibenclamide, glimepiride, repaglinide and meglitinide non-specifically block both SUR1 and SUR2 receptor-containing channels, altering ischaemic preconditioning of the heart and increasing the susceptibility of the diabetic myocardium to ischaemic insult [34, 35] . Low risk of hypoglycaemia and cardiovascular neutrality are considered to be beneficial features of gliclazide over other sulfonylureas [36, 37] .
Interestingly, gliclazide induced the expression of insulin promoter factor 1 (PDX1), a transcription factor involved in b-cell differentiation, as well as Ki67, a cellular marker of proliferation and regeneration. Even though the issue of b-cell regeneration in humans is a subject of intensive study [38] , research data suggest that gliclazide could have beneficial effects on b-cell differentiation [39] . Gliclazide has also been demonstrated to stimulate differentiation but not and proliferation of brown and white adipocytes by downregulating epidermal growth factor receptor (EGFR) signalling and also to inhibit the peroxisome proliferator-activated receptor-c (PPAR-c) activity of mature adipocytes, whereas this effect has not been observed in glibenclamide [40] . Stimulation of b-cell differentiation and proliferation by gliclazide along with the propensity to reduce b-cell apoptosis suggest that this agent could contribute to the b-cell mass maintenance [41] .
Extrapancreatic Effect of Gliclazide
Compared to other sulphonylurea drugs, gliclazide exhibits a pleiotropic action outside pancreatic b cells, the so-called extrapancreatic effects, such as antiinflammatory and cellular protective effects, which might be beneficial in the treatment of T1DM [26] . At least part of these effects are connected with ATP-sensitive potassium channels that are present in various cells, including smooth, cardiac and skeletal muscle cells and in neurons [42] .
The first evidence for the extrapancreatic effect of sulphonylureas was the demonstration of a potentiation of the insulin efficacy in pancreatectomized dogs. This sulphonylurea effect was predominantly mediated through an inhibition of hepatic glucose production [43] . Gliclazide extrapancreatic effects include stimulation of glucose transport and metabolism, stimulation of glycolytic and inhibition of gluconeogenic pathways, stimulation of glucose uptake and increase in plasma membrane content of glucose transportes in skeletal muscles [28, 42] . These extrapancreatic effects of gliclazide may be of great importance in T1DM, especially when combined with other hypoglycaemic agents.
Antioxidative Properties of Gliclazide
Diabetic patients are exposed to oxidative stress and the increased production of oxygen free radicals that reduces the protective capabilities of antioxidant defence systems. In those patients, the increased production of oxygen free radicals may be linked to the development of chronic complications of diabetes causing various forms of tissue damage that lead to progressive deterioration of b cell function and suppression of insulin biosynthesis [44] [45] [46] . The possible sources of oxidative stress in diabetes might include shifts in redox balances, decreased potential of antioxidant defence enzymes such as catalase (CAT) and superoxide dismutase (SOD), reduced amounts of low molecular weight antioxidants such as reduced glutathione (GSH) and vitamin E and auto-oxidation of glucose and. However, the exact mechanism by which oxidative stress may contribute to the development of diabetic complications is still to be elucidated [46] . Due to fact that oxygen free radicals mediate b-cell destruction in the experimental model of streptozocin-induced diabetes, it may be suggested that oxidative stress also may play a huge role in the initial stages of T1DM. [47] .
Besides its hypoglycaemic effect, gliclazide has been shown to possess antioxidant properties related to the unique aminoazabicyclo-octane ring in its structure. Antioxidant property of gliclazide is independent of its antihyperglycaemic activity [48] . Scott et al. [49] found that gliclazide is a powerful free radical scavenger in vitro. Gliclazide reduces oxidative stress of b-cells induced by hydrogen-peroxide and maintains a higher cellular viability, suggesting that gliclazide may be effective in preventing b-cells from the toxic action of reactive oxygen species in diabetes. In addition, Del Guerra et al. [41] confirmed that chronic treatment of gliclazide protects pancreatic b cells from apoptosis. Beyond its own antioxidant properties, gliclazide protects against oxidative stress by upregulating the antioxidant defence status of the b cells, increasing superoxide dismutase and catalase activity [27] . Onozoto et al. [50] examined renoprotective effect of gliclazide finding the reduction of oxidative stress in diabetic rats fed a high cholesterol diet with the decrease in renal NAD(P)H oxidase expression, enhanced mitochondrial antioxidant manganese superoxide dismutase (MnSOD) and (endothelial nitric oxide synthase) eNOS expression suggesting beneficial effect on glomerular macrophage infiltration and mesangial expansion. These beneficial effects were not observed with the other sulphonylurea glibenclamide.
Furthermore, the beneficial effects of gliclazide on cellmediated LDL oxidation and monocyte adhesion to endothelial cells induced by oxidatively modified LDL may be useful in the prevention of atherosclerosis in diabetic patients [51] . Besides, gliclazide reduces platelet reactivity that is also related to a reduction in oxidative stress as well [48] .
In diabetes, therefore, where increased glycation and oxidation are the basis of pathogenesis of diabetic vascular events, drugs such as gliclazide with its antioxidant activities may have an enhanced therapeutic role [48] .
Bile Acids as Hypoglycaemic Agents
Recent discoveries have demonstrated that bile acids secreted into the intestines not only act as digestive surfactants that facilitate the absorption of lipophilic xenobiotics, but act also as signalling, endocrine molecules regulating the glucose, lipid and energy metabolism through complex and interrelated pathways [52] [53] [54] .
The production of bile acids is localized primarily in hepatocytes where primary bile acids are synthesized directly from cholesterol. In humans, the most important are cholic acid and chenodeoxycholic acid, which make up 80% of all bile acids. The action of intestinal microbiota on primary bile acids results in the formation of secondary bile acid species: deoxycholic and lithocholic acids, derived from cholic acid and chenodeoxycholic acid, respectively, and thus, microfloral composition is directly linked to secondary bile acid production and bile acid composition [55] .
A growing body of evidence has shown that significant inflammation and disturbed bile acid homeostasis are associated with T1DM [56, 57] . What is still to be elucidated is whether the changes in bile acids homeostasis are either a cause or a consequence of the metabolic disturbances observed in the course of diabetes [52, 54] .
Potential therapeutic use of bile acids in diabetes can be achieved through two main applications: as hypoglycaemic agents [58] and as absorption-enhancing agent in alternative manner of insulin delivery [5] . Bile acid implications in glucose regulation are mediated by activation of nuclear and membrane-bound G protein-coupled signalling pathways [55, [59] [60] [61] .
Both endogenous and exogenous bile acids are recognized as ligands for intracellular nuclear farnesoid X receptor (FXR), with CDCA being the most potent endogenous FXR ligand. Secondary bile acids, DCA and LCA can also activate FXR, but to a much lesser extent than CDCA. CA is a weak FXR agonist, whereas hydrophilic UDCA cannot activate FXR [52, 62, 63] . FXR is ubiquitously expressed in organism, most abundantly expressed in entero-hepatic tissues. The activation of FXR is involved in various metabolic processes, including hepatic gluconeogenesis, lipogenesis, fatty-acid oxidation, insulin sensitivity, and triglyceride-rich lipoprotein clearance [52, 62, 64] . By activating FXR, bile acids have been shown to decrease hepatic glucose production, increase glycogenesis, improve insulin synthesis and secretion and improve hepatic and peripheral insulin sensitivity [65] [66] [67] [68] . The possibility that FXR activation inhibits hepatic gluconeogenesis to lower fasting plasma glucose has been extensively investigated. Yamagata et al. [66] have found that bile acids inhibit expression of gluconeogenic genes for phosphoenolpyruvate carboxykinase (PEPCK), fructose 1,6-bis phosphatase (FBP1) and glucose-6-phosphatase (G6Pase) through the interaction of small heterodimer partner (SHP) with hepatocyte nuclear factor 4 (HNF-4) or forkhead transcription factor Foxo1 in in vivo and in vitro experiments. However, it is suggested that the role of FXR in plasma glucose levels regulation may not be solely dependent on the direct inhibition of hepatic gluconeogenesis and that some other mechanisms may be also involved. Duran-Sandoval et al. [69] demonstrated that FXR was decreased in animal models of diabetes and normalized upon insulin supplementation. Furthermore, they showed that glucose-stimulated FXR gene expression, whereas insulin counteracted this effect. Therefore, FXR might be one of the molecular links between altered bile acid metabolism and diabetic states.
On the other hand, the cell surface G protein-coupled bile acid receptor 1, TGR5 (also known as GPBAR1) agonism constitutes a gateway to the non-genomic functions of bile acids. The activation of TGR5 by bile acids in brown adipose tissue and muscles has been shown to trigger an increase in energy expenditure, to attenuate the diet-induced obesity and improve insulin signalling [70, 71] . TGR5 is also expressed in entero-endocrine L cells of the small and large intestine, which secrete glucagon-like peptide-1 (GLP-1), a hormone with glucosedependent insulinotropic properties. GLP-1 acts via its own G protein-coupled receptor which has a varied tissue distribution in humans. Amongst other tissues, GLP-1 receptors are found in the pancreas, where they stimulate glucose-dependent release of insulin from b cells without stimulating the release of glucagon from a-cells. Furthermore, GLP-1 delays the gastric emptying, whereas its mechanisms achieved via hypothalamus have anorectic properties, increasing the satiety and reducing the food intake [72, 73] . Bile acids have been shown to increase GLP-1 secretion from L cells both in vitro and in vivo, in a TGR5-dependent manner, stimulating release of insulin from the pancreatic b cells and reducing postprandial glycaemia [74, 75] . TGR5 is activated by nanomolar concentrations of LCA and micromolar concentrations of CA, DCA and CDCA [59, 60, 76, 77] .
Thus, therapeutic targeting of these receptors via specific and potent agonists including bile acids opens new perspectives for the treatment of numerous metabolic disorders, including the diabetes mellitus.
The Role of Gut Microflora and Probiotics in T1DM
Under normal physiological conditions, the gut microflora represents a homeostatic ecosystem with several vital functions including food digestion, metabolism of many endogenous substances such as bilirubin, cholesterol, bile acids, steroid hormones, fatty acids, synthesis of vitamins B and K, drug metabolism, development of optimally functioning immune system and intestinal epithelial barrier and protection against potentially pathogenic bacteria pathogens [78, 79] . Disturbance of this equilibrium can result in dysbiosis and increase risk of disease. Altered community composition has been established in a number of inflammatory and autoimmune diseases [78, 80] . Even though data are still inconclusive, there are strong indications that gut microbiota dysbiosis plays an essential role in T1DM [81] . In healthy adults, 80% of the identified faecal microbiota can be classified into three main phyla: Bacteroidetes, Firmicutes and Actinobacteria. Initial findings indicate that the intestinal microbiome of individuals at risk of developing T1DM and in patients with established disease is different to that of healthy individuals [82] . Giongo et al. found an increased ratio of Bacteroidetes vs Firmicutes in four children who became b cell autoantibody positive during the follow-up [8] . Furthermore, Vaarala and coauthors [83] confirmed that faecal microbiota of children with b cell autoimmunity have increased the number of members belonged to Bacteroidetes phylum and decreased the number of butyrate-producing bacteria. These changes may be the reason of subclinical small intestinal inflammation, increased gut permeability and dysregulation of oral tolerance in T1DM. The mechanisms mediating such an effect are still to be elucidated, although intestinal butyrate is perceived to be beneficial being the principal energy source for epithelial cells in the colon and is capable of regulating the assembly of tight junctions and gut permeability [82] .
Evidence from animal models suggests that gut microbiota manipulation by administering probiotic bacteria might be an attractive approach for future prevention of T1DM in genetically susceptible individuals [81] . World Health Organization (WHO) defines probiotics as live microorganisms which, when administered in adequate amounts, confer a health benefit on the host [84] . The mechanisms by which probiotics modulate the intestinal microbiota composition include reduction of luminal pH, secretion of antimicrobial compounds (bacteriocins), induction of the production of antimicrobial compounds (defensins) by the host, competition for nutrients and prevention of bacterial adhesion and evasion of epithelial cells [85] . Combinations of different bacterial strains can be used as probiotics, but the certain bacterial genera, Lactobacillus and Bifidobacterium, are the most common choices [86, 87] . It should be mentioned that different bacterial strains, even within the same species, may exhibit different effects, and thus the main goal is the proper selection and identification of a certain strain [88] .
There are reports in the literature that probiotic treatment can be useful in T1DM, but up to now, far too little attention has been paid to elucidation of the mechanisms involved. A possible explanation for hypoglycaemic effect of probiotics is the stimulation of intestinal microbiota to produce GLP-1 or other insulinotropic polypeptides or other factors that induce glucose uptake by the muscles, or stimulate the liver to assimilate more blood glucose in the form of glycogen [4] .
Previous and Current study on Gliclazide-Bile Acids-Probiotics Interactions in the Treatment of T1DM
Our team is intensively studying the relationship between antidiabetic drugs, insulin, gliclazide, bile acids and probiotics regarding the potential application in metabolic disorders with special emphasis on diabetes mellitus. It has been confirmed that some patients whose T2DM progresses to T1DM have better control over glycaemia when continue to use gliclazide than those patients who use insulin alone. Fallucca et al. showed that combined insulingliclazide treatment improves b cell function and glycaemic control during the first 18 months of T1DM, inducing a major reduction of the insulin need compared to patients treated with insulin alone [89] .
Studies conducted by our group have shown that a multi-therapeutic approach incorporating bile acids and probiotics, as adjunct therapy in a rat model of T1DM, exerted even better glycaemic control and resulted in ameliorating complications, than when each treatment was administered alone [57, 90, 91] .
Examining the beneficial effects of probiotics in T1DM, our group [57] have found that probiotic treatment alone had no effect on glycaemia in healthy rats, but significantly reduced the elevated blood glucose levels by up to twofold in diabetic rats. Although the exact mechanisms for these effects have not been elucidated yet, what is determined is that they are not dependent on insulin. As previously mentioned, a possible explanation for hypoglycaemic effect is mediated by production of insulinotropic polypeptides and GLP-1 by intestinal microbiota.
Considering the possibility that chronic treatment with probiotics can change tissues permeability, we investigated the influence of probiotic treatment on the ex vivo permeation of gliclazide, in healthy and diabetic rats. Our results confirmed that chronic treatment with probiotics for 3 days modified the gliclazide fluxes in both healthy control and diabetic animals in a different manner. Treatment with probiotics of healthy rats reduced gliclazide permeation and increased its secretion through the ileum as a consequence of a sixfold reduction of the mucosal to serosal absorption Jss (MtoS) and a twofold stimulation of mucosal to serosal absorption Jss (MtoS) of gliclazide compared to untreated animals. In contrast, in diabetic animals, treatment with probiotics stimulated the net absorption of gliclazide as a result of increased Jss (MtoS) and reduced Jss (StoM) to levels similar to that of healthy untreated animals. The reduction of Jss (MtoS) in healthy rats after probiotics administration could be explained by the production of bacterial metabolites that upregulate the efflux drug transporters Mrp2 and Mrp3 that are responsible for gliclazide transport and whose function is disturbed in T1DM since hyperglycaemia itself directly reduced the activity of transport proteins. Accordingly, the restored fluxes of gliclazide after probiotic treatment in diabetic rats suggest the normalization of the functionality of the drug transporters, resulting in a net absorption [92] .
It has been shown that 12-monoketocholic acid sodium salt (12-MKC) interaction with probiotics also induced the significant modifications of the gliclazide pharmacokinetics. In the tissues of healthy rats treated with probiotics, 12-MKC stimulated the net absorption of gliclazide by stimulating the absorptive and reducing the secretory unidirectional fluxes. On the other hand, in tissues from diabetic rats treated with probiotics, 12-MKC had no effect. The main mechanism involved in increased absorption of gliclazide in healthy rats treated with probiotics was ascribed to the inhibition of Mrp2 by divalent bile salts produced upon degradation of 12-MKC by bacterial polypeptides, indicating different metabolic profiles in diabetic rat tissues [90] .
Furthermore, examining the influence of probiotic treatment on gliclazide absorption in vivo, it was indicated that probiotic treatment reduced the gliclazide bioavailability in healthy rats, while it exerted the opposite effect in diabetic rats. There are several possible explanations for this result. One explanation could be the activation of efflux drug transporter, multidrug resistance-associated protein 2 (Mrp2) in healthy rats, which may reduce the absorption of gliclazide. On the other hand, the rats with alloxan-induced diabetes have impaired function of this transporter that could not be overcome by probiotic intake, resulting in a higher absorption rate of gliclazide. Another possibility is the formation of a ''thicker'' layer that represents a physical barrier formed as a result of chronic probiotic treatment that may reduce gliclazide absorption in healthy animals. In addition, probiotics may lead to gliclazide degradation in healthy rats that also may be the reason of decreased bioavailability [57] .
Regarding the application of bile acids in T1DM, it has been shown that ursodeoxycholic acid administered to alloxan-induced diabetic rats ameliorated mitochondrial dysfunction [93] . Kars et al. [94] showed that tauroursodeoxycholic acid improved sensitivity of muscle tissues to insulin and enhanced glucose uptake, which suggests that it may potentiate insulin-mimetic effects by affecting directly muscle cells and blood glucose level. In a more recent study, taurocholic acid modulated glucose uptake by the gut and increased glucagon-like peptides as well as C-peptide ratio with glucose [95] . Hypoglycaemic effects of bile acids may be partly explained by activation of nuclear and membrane receptors, as previously mentioned. Via FXR activation, bile acids have been shown to decrease the hepatic glucose production as a consequence of down-regulation of the gluconeogenic program [52] .
Our group focused on the effects of 12-MKC, which is a stable semisynthetic primary bile acid (cholic acid analogue) with low toxicity [96] . Due to its specific structure and drug permeation-enhancing activity, 12-MKC has been shown to enhance the nasal absorption of insulin in rats [97] . Intravenous administration of 12-MKC to healthy and diabetic rats had no effect on blood glucose level. However, oral administration of 12-MKC to diabetic rats produced a significant effect 3 h after administration. These effects may be ascribed to metabolic activation of 12-MKC in the gut [91] .
Diabetic rats treated with 12-MKC and pre-treated with probiotics showed lower weight loss, lower urine production and water consumption, and improvement in behaviour and survival rate compared to control diabetic rats, not pre-treated with probiotics indicating the synergistic role in ameliorating diabetes complications [91] .
Results of our group confirmed that there are significant modifications of pharmacokinetic parameters of 12-MKC upon probiotic treatment after oral administration compared to intravenous administration where no effect on 12-MKC pharmacokinetics was observed in either healthy or diabetic rats with and without probiotic pretreatment. Namely, probiotic treatment reduced the oral bioavailability and delayed the absorption of 12-MKC when given alone to healthy rats [91] , which similarly as with gliclazide, may be explained by probiotic-induced increase of pre-systemic metabolism of 12-MKC, as it is confirmed that gut microflora and probiotic bacteria possess huge metabolic activity that may largely influence the pharmacokinetic properties of orally administered drugs and other xenobiotics [86] .
Our group also studied pharmacokinetics and glucoselowering activity of gliclazide alone and in combination with 12-MKC in a rat model of T1DM. It have been demonstrated that gliclazide alone had no effect on blood glucose levels whereas 12-MKC did [97] . Interestingly, the combination of 12-MKC and gliclazide exerted even a better hypoglycaemic effect compared to 12-MKC alone [98] . This synergistic effect could be due to gliclazide enhancing the production and/or absorption of 12-MKC active metabolites in the gut. Despite the lower gliclazide bioavailability in type 1 diabetic rats compared to healthy controls, it was found that the hypoglycaemic effect of the combined mixture of 12-MKC and the antidiabetic drug gliclazide was significantly greater in diabetic rats, suggesting that hypoglycaemic effects are independent on gliclazide concentration. As gliclazide itself does not exhibit the hypoglycaemic effect in a rat model of T1DM, it can be concluded that gliclazide potentiates hypoglycaemic effect of 12-MKC [98] . In addition, we have shown that the hypoglycaemic effect was the most pronounced when diabetic rats were pre-treated with probiotics compared to those who were gavaged with the combination of 12-MKC and gliclazide without probiotics [91] .
Even though the exact mechanism of interaction, at the molecular level is still unknown, there is a strong synergistic effect between bile acids, gliclazide and probiotic pretreatment in T1DM, resulting in a profound hypoglycaemic effect and sound reduction in the diabetic complications in treated diabetic animals. In addition, our findings suggest that pharmacological or physiological interactions between bile acids, probiotics and gliclazide result in more pronounced beneficial effects in T1DM following their concomitant administration in comparison with the application of gliclazide alone [4] . Potential effects of concomitant administration of gliclazide, bile salts and probiotics in T1DM are summarized and presented in Fig. 1 . However, exact mechanisms connecting intertwined signalling network between proposed agents still have to be elucidated.
Novel Gliclazide Formulations with Bile Acids
Recent studies confirmed benefits of bile acids in various formulations with antidiabetic drugs indicating their great potential in the treatment of diabetes mellitus [99] [100] [101] [102] [103] . It is well known that oral delivery of insulin is challenging and must overcome the barriers of gastric and enzymatic degradation as well as low permeation across the intestinal epithelium [104] . Our team showed that bile acids may act as absorption-enhancing agents in alternative manner of insulin delivery. The synthetic derivative, 12-MKC, is proved to be an especially good promoter of nasal absorption of insulin in rats [105] .
Regarding the development of new pharmaceutical formulations, our group designed a novel and stable oral delivery system for the targeted delivery of gliclazide and optimized efficacy through the incorporation with cholic acid. This microencapsulated formulation consists of gliclazide formulated in biodegradable polymer, sodium alginate, mixed with cholic acid [101] . It was demonstrated that this new formulation, exhibited colon-targeted delivery and the addition of cholic acid prolonged gliclazide release suggesting its suitability for the sustained and targeted delivery of gliclazide and cholic acid to the lower intestine [106] . Furthermore, microencapsulated formulation of gliclazide with more lypophilic, deoxycholic acid, showed also the potential to enhance gliclazide pharmacokinetic and pharmacodynamic effects in rat model of T1DM [99] . The new microencapsulated formulation has good structural properties and may be useful for the oral delivery of gliclazide.
The potential of bile acids in pharmaceutical formulations may be achieved through their effect on drug transport across various membranes [107, 108] . Their role in promoting drug permeation has been experimentally illustrated through different administration routes [108] . It has been demonstrated that bile acids enhance the permeation of gliclazide through the ileal mucosa [109] and through the blood-brain barrier in type 1 diabetic rats [110] .
It is well known that effects of bile acids on drug permeation correlate with their hydrophobicity. However, more hydrophobic bile acids have lower critical micellar concentrations (CMC) and more cytotoxic properties [5, 108] .
Toxicity of Bile Acids
In supraphysiological concentrations, bile acids may cause the disruption of cell membranes through their detergent effect on lipid components and can promote the generation of reactive oxygen species that, in turn, oxidatively modify lipids, proteins, and nucleic acids, and eventually cause hepatocyte necrosis and apoptosis. The accumulation of bile acids in the systemic circulation in higher concentrations may lead to endothelial injury in lungs and kidney. In addition, bile acids may behave as cancer promoters in gastrointestinal cells through an indirect mechanism involving oxidative stress and DNA damage [111] . Intestinal bacteria can decrease the toxicity of the bile acid transforming a-OH bile acids to b-OH bile acids by reactions of oxidations and epimerizations that require the presence of specific hydroxysteroid dehydrogenases found in many Clostridia and a few other bacteria [112] . Taking into account the relationship between bile acid structure and the effect induced in the cell membrane, it is possible to reduce the toxicity of bile acids by minor structural modifications of natural bile salts. Accordingly, it has been shown that replacing hydroxyl groups in cholic acid with keto groups produces significantly less surface active and less lipophilic bile salts with higher CMC and consequently with diminished membrane toxicity [113] . Therefore, much attention has been paid to pharmacological studies of 12-MKC, a stable semisynthetic primary bile acid, cholic acid analogue, as absorption enhancer that has been proven to possess great permeation-enhancing activity but has significantly lower toxicity [96] .
Conclusion
Multi-therapeutic approach in treating diabetes with better efficacy continues to gain interest worldwide due to continuous rise of the disease prevalence and health fiscal costs. The focus is on novel non-insulin therapeutic approaches that reduce hyperglycaemia and reduce diabetic complications without increasing the risk of hypoglycaemia or other adverse events. Evidently, patients with T1DM have completely different gut biomorphology and response compared to healthy which should be taken into account when discussing multidrug approach to the disease. Accordingly, future therapy should not only focus on repairing glucose imbalance but also in targeting the disturbances in bile acids and gut microbiota composition. Although gliclazide has been used for decades to treat T2DM, results from in vivo experiments are pointing to its role in T1DM as well, particularly in combination with other hypoglycaemic agents. Potential of bile acids, probiotics and gliclazide in T1DM is illustrated by the reduction in blood glucose levels and improvement in diabetic complications. Given that these interactions of probiotics with bile acids and antidiabetics like gliclazide are different between healthy and diabetic animals, future research should therefore concentrate on the investigation of the exact mechanisms responsible for alterations of the pharmacokinetic and pharmacodynamic properties. Although the exact mechanisms connecting intertwined signalling network between proposed agents still have to be elucidated, implications of FXR and TGR5 mediated pathways activated by the co-administration of bile acids with probiotics, as the possible explanation for their beneficial effects in diabetes mellitus, would be an interesting area for this investigation. 
